First drug-like compounds to inhibit elusive cancer-linked enzymes developed

Google+ Pinterest LinkedIn Tumblr +

A team of scientists from the University of Michigan Rogel Cancer Center, USA, has developed the first drug-like compounds to inhibit a key family of enzymes whose malfunction is associated with several types of cancer, including an aggressive form of childhood leukaemia.

The enzymes — known as the nuclear receptor-binding SET domain (NSD) family of histone methyltransferases — have long been an attractive drug target, but efforts to attack them have previously proved elusive because the shape of the binding sites in these enzymes makes it difficult for drug-like molecules to bind to it.

The research team — led by Tomasz Cierpicki, Ph.D., and Jolanta Grembecka, Ph.D. — used a variety of techniques including X-ray crystallography and nuclear magnetic resonance to develop first-in-class inhibitors of a key protein known as NSD1, according to findings published in Nature Chemical Biology.

The team’s lead compound — known as BT5 — showed promising activity in leukaemia cells with the NUP98-NSD1 chromosomal translocation that is seen in a subset of paediatric leukaemia patients.

“Our study, which was years in the making, demonstrates that targeting this key enzyme with small-molecule inhibitors is a feasible approach,” says Cierpicki, an associate professor of biophysics and pathology at U-M. “These findings will facilitate the development of the next generation of potent and selective inhibitors of these enzymes, which are overexpressed, mutated or undergo translocations in several types of cancer.”


Source: Michigan Medicine – University of Michigan

Share.

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.